Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 9/20 | 0.55 |
| ▸ | DRD4 | P21917 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | DRD5 | P21918 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7960011 | 0.76 | SIGMAR1 (0.52) | HTR1ADRD4KDM4EGAADRD2 | |
| SCHEMBL7960186 | 0.73 | HTR1A (0.54) | HTR1ADRD4KDM4EGAADRD2 | |
| SCHEMBL6599536 | 0.68 | HTR1A (1.00) | HTR1A | |
| SCHEMBL6598139 | 0.68 | HTR1A (1.00) | HTR1ADRD4DRD2DRD3 | |
| SCHEMBL14440419 | 0.67 | HTR1A (0.61) | HTR1ADRD4KDM4EGAADRD2 | |
| SCHEMBL10366646 | 0.65 | KDM4E (0.61) | HTR1ADRD4KDM4EGAADRD2 | |
| SCHEMBL7961060 | 0.65 | HTR1A (0.54) | HTR1ADRD2DRD1DRD5HTR2A | |
| SCHEMBL7961169 | 0.65 | MAPT (0.45) | HTR1ADRD2 | |
| SCHEMBL18754269 | 0.65 | KDM4E (0.75) | HTR1ADRD4KDM4EGAADRD2 | |
| SCHEMBL10486189 | 0.65 | KCNH2 (0.70) | HTR1ADRD2DRD1DRD5HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6187774-B1 | N-PIPERAZINYLALKYLINDAZOLE DERIVATIVES; PSYCHOLOGICAL DISORDERS, SCHIZOPHRENIA; SIDE EFFECT REDUCTION | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2001-02-13 | — | — | US | disclosed |
| EP-0885883-A1 | FUSED HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL APPLICATIONS THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1998-12-23 | — | — | EP | disclosed |